Increase in demand for targeted medicines is propelling the companion diagnostic tests in oncology market size. Companion diagnostics play a significant role in the development of targeted drugs for cancer treatment.
Integration of Artificial Intelligence (AI) in companion diagnostics is boosting the companion diagnostic tests in oncology market trajectory. The combined use of AI and companion diagnostics can help increase patient access to targeted treatments.
Key players operating in the global companion diagnostic tests in oncology market are exploring the potential of genomics to offer quick and precise detection of cancer through non-invasive blood tests.
Oncology companion diagnostics is used to match a patient to a specific therapy or drug. In other words, it helps to determine if a patient should be the receptor of a drug or not. Companion diagnostics can monitor response to treatment with a particular therapeutic product. This aids in adjusting treatment to achieve improved safety or effectiveness.
Advancements in genomics and genetic sequencing are major companion diagnostic tests in oncology market trends. Next-generation Sequencing (NGS)-based companion diagnostic tests unlock the molecular information from every patient’s tumor genome to provide guidelines regarding treatment decisions for.
Personalized medicine and companion diagnostics go hand-in-hand. Companion diagnostics help decide which treatments to offer patients and which dosage to give, tailored specifically to the patient. However, the cost of personalized immunotherapies is quite high. For instance, Novartis’ KYMRIAH (approved CAR T-cell treatment) alone costs from US$ 373,000 to US$ 475,000. Hence, high cost of personalized immunotherapies is likely to limit the companion diagnostic tests in oncology market growth in the near future.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
In-depth understanding of biomarkers or genetic characteristics of an individual can help customized treatment strategies. Biopharmaceutical and pharmaceutical companies are implementing several patient-centric diagnostic frameworks at the initial stages of drug development to provide targeted therapies. This, in turn, is boosting the demand for companion diagnosis, thereby fueling the companion diagnostic tests in oncology market dynamics.
Extensive research is conducted to devise targeted therapies for treating cancerous diseases such as Kaposi’s cancer, liver cancer, multiple myeloma, ovarian cancer, metastatic breast cancer, pancreatic cancer, advanced colorectal cancer, and non-small cell lung cancer. Disadvantages of chemotherapy, such as damage caused to healthy cells, are prompting the use of cancer biomarker testing, precision medicine in oncology, and molecular diagnostic tests for cancer. This is projected to drive the market development in the next few years.
As per the World Cancer Research Fund International, the year 2020 alone witnessed 18.1 million cancer cases. Rise in prevalence of cancer and surge in need for targeted therapy are contributing to the companion diagnostic tests in oncology market demand.
Vendors operating in the companion diagnostic tests in oncology market landscape are investing in the R&D of AI-assisted diagnostics. AI is gaining traction in clinical diagnostics, with radiology and imaging being the early adopters of the technology.
Rise in investment in digital pathology and AI is projected to boost the market statistics during the forecast period. Digital pathology can improve workflows and increase efficacy for laboratory pathology. The integration of AI can further improve productivity and shorten turnaround time in pathology laboratories.
Major diagnostics service providers are incorporating AI algorithms in their digital pathology software. In October 2023, Roche partnered with Ibex Medical Analytics and Amazon Web Services to enable pathology laboratories to access Ibex’s AI-powered decision support tools to aid in the diagnosis of breast and prostate cancer.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest companion diagnostic tests in oncology market analysis, North America held largest share in 2023. Approval and launch of new products is fueling the market statistics in North America. In 2023, the U.S. FDA approved the FoundationOne CDx for use as a companion diagnostic to identify patients with advanced hormone receptor–positive, HER2-negative advanced breast cancer who may be eligible for treatment with the combination of capivasertib (Truqap) and fulvestrant (Faslodex).
Major companies in the companion diagnostic tests in oncology market are focusing on launching new products to expand their product portfolio. Abbott, F. Hoffmann-La Roche AG, Genomic Health, Inc., QIAGEN, Agilent Technologies, Inc., AGENDIA N.V., bioMérieux SA, Illumina, Inc., Siemens Healthineers, Thermo Fisher Scientific Inc., and BioGenex are key players operating in the companion diagnostic tests in oncology industry.
These companies have been profiled in the companion diagnostic tests in oncology market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 6.1 Bn |
| Market Forecast (Value) in 2034 | US$ 17.0 Bn |
| Growth Rate (CAGR) | 9.5% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 6.1 Bn in 2023
It is projected to grow at a CAGR of 9.5% from 2024 to 2034
Increase in demand for targeted medicines and integration of artificial intelligence (AI) in companion diagnostics
North America was the dominant region in 2023
Abbott, F. Hoffmann-La Roche AG, Genomic Health, Inc., QIAGEN, Agilent Technologies, Inc., AGENDIA N.V., bioMérieux SA, Illumina, Inc., Siemens Healthineers, Thermo Fisher Scientific Inc., and BioGenex
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Companion Diagnostic Tests in Oncology Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, 2020 - 2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Detection Technique
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Detection Technique, 2020 - 2034
6.3.1. Protein Detection
6.3.1.1. Immunohistochemistry
6.3.2. DNA Detection
6.3.2.1. Polymerase Chain Reaction (PCR)
6.3.2.2. Next-generation Sequencing (NGS)
6.3.2.3. In Situ Hybridization
6.3.3. Others
6.4. Market Attractiveness, by Detection Technique
7. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Biomarker
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Biomarker, 2020 - 2034
7.3.1. EGFR
7.3.2. KRAS
7.3.3. HER2
7.3.4. BRAF V600E
7.3.5. Others
7.3.6. 7.4 Market Attractiveness, by Biomarker
8. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Cancer Type
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Cancer Type, 2020 - 2034
8.3.1. Breast Cancer
8.3.2. Lung Cancer
8.3.3. Colorectal Cancer
8.3.4. Liver Cancer
8.3.5. Melanoma
8.3.6. Others
8.4. Market Attractiveness, by Cancer Type
9. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020 - 2034
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.3.3. Diagnostic Labs
9.3.4. Others
9.4. Market Attractiveness, by End-user
10. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020 - 2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Companion Diagnostic Tests in Oncology Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Detection Technique, 2020 - 2034
11.2.1. Protein Detection
11.2.1.1. Immunohistochemistry
11.2.2. DNA Detection
11.2.2.1. Polymerase Chain Reaction (PCR)
11.2.2.2. Next-generation Sequencing (NGS)
11.2.2.3. In Situ Hybridization
11.2.3. Others
11.3. Market Attractiveness, by Detection Technique
11.4. Market Value Forecast, by Biomarker, 2020 - 2034
11.4.1. EGFR
11.4.2. KRAS
11.4.3. HER2
11.4.4. BRAF V600E
11.4.5. Others
11.5. Market Attractiveness, by Biomarker
11.6. Market Value Forecast, by Cancer Type, 2020 - 2034
11.6.1. Breast Cancer
11.6.2. Lung Cancer
11.6.3. Colorectal Cancer
11.6.4. Liver Cancer
11.6.5. Melanoma
11.6.6. Others
11.7. Market Attractiveness, by Cancer Type
11.8. Market Value Forecast, by End-user, 2020 - 2034
11.8.1. Hospitals
11.8.2. Specialty Clinics
11.8.3. Diagnostic Labs
11.8.4. Others
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country, 2020 - 2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Detection Technique
11.11.2. By Biomarker
11.11.3. By Cancer Type
11.11.4. By End-user
11.11.5. By Country
12. Europe Companion Diagnostic Tests in Oncology Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Detection Technique, 2020 - 2034
12.2.1. Protein Detection
12.2.1.1. Immunohistochemistry
12.2.2. DNA Detection
12.2.2.1. Polymerase Chain Reaction (PCR)
12.2.2.2. Next-generation Sequencing (NGS)
12.2.2.3. In Situ Hybridization
12.2.3. Others
12.3. Market Attractiveness, by Detection Technique
12.4. Market Value Forecast, by Biomarker, 2020 - 2034
12.4.1. EGFR
12.4.2. KRAS
12.4.3. HER2
12.4.4. BRAF V600E
12.4.5. Others
12.5. Market Attractiveness, by Biomarker
12.6. Market Value Forecast, by Cancer Type, 2020 - 2034
12.6.1. Breast Cancer
12.6.2. Lung Cancer
12.6.3. Colorectal Cancer
12.6.4. Liver Cancer
12.6.5. Melanoma
12.6.6. Others
12.7. Market Attractiveness, by Cancer Type
12.8. Market Value Forecast, by End-user, 2020 - 2034
12.8.1. Hospitals
12.8.2. Specialty Clinics
12.8.3. Diagnostic Labs
12.8.4. Others
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Detection Technique
12.11.2. By Biomarker
12.11.3. By Cancer Type
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Companion Diagnostic Tests in Oncology Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Detection Technique, 2020 - 2034
13.2.1. Protein Detection
13.2.1.1. Immunohistochemistry
13.2.2. DNA Detection
13.2.2.1. Polymerase Chain Reaction (PCR)
13.2.2.2. Next-generation Sequencing (NGS)
13.2.2.3. In Situ Hybridization
13.2.3. Others
13.3. Market Attractiveness, by Detection Technique
13.4. Market Value Forecast, by Biomarker, 2020 - 2034
13.4.1. EGFR
13.4.2. KRAS
13.4.3. HER2
13.4.4. BRAF V600E
13.4.5. Others
13.5. Market Attractiveness, by Biomarker
13.6. Market Value Forecast, by Cancer Type, 2020 - 2034
13.6.1. Breast Cancer
13.6.2. Lung Cancer
13.6.3. Colorectal Cancer
13.6.4. Liver Cancer
13.6.5. Melanoma
13.6.6. Others
13.7. Market Attractiveness, by Cancer Type
13.8. Market Value Forecast, by End-user, 2020 - 2034
13.8.1. Hospitals
13.8.2. Specialty Clinics
13.8.3. Diagnostic Labs
13.8.4. Others
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Detection Technique
13.11.2. By Biomarker
13.11.3. By Cancer Type
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Companion Diagnostic Tests in Oncology Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Detection Technique, 2020 - 2034
14.2.1. Protein Detection
14.2.1.1. Immunohistochemistry
14.2.2. DNA Detection
14.2.2.1. Polymerase Chain Reaction (PCR)
14.2.2.2. Next-generation Sequencing (NGS)
14.2.2.3. In Situ Hybridization
14.2.3. Others
14.3. Market Attractiveness, by Detection Technique
14.4. Market Value Forecast, by Biomarker, 2020 - 2034
14.4.1. EGFR
14.4.2. KRAS
14.4.3. HER2
14.4.4. BRAF V600E
14.4.5. Others
14.5. Market Attractiveness, by Biomarker
14.6. Market Value Forecast, by Cancer Type, 2020 - 2034
14.6.1. Breast Cancer
14.6.2. Lung Cancer
14.6.3. Colorectal Cancer
14.6.4. Liver Cancer
14.6.5. Melanoma
14.6.6. Others
14.7. Market Attractiveness, by Cancer Type
14.8. Market Value Forecast, by End-user, 2020 - 2034
14.8.1. Hospitals
14.8.2. Specialty Clinics
14.8.3. Diagnostic Labs
14.8.4. Others
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Detection Technique
14.11.2. By Biomarker
14.11.3. By Cancer Type
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Companion Diagnostic Tests in Oncology Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Detection Technique, 2020 - 2034
15.2.1. Protein Detection
15.2.1.1. Immunohistochemistry
15.2.2. DNA Detection
15.2.2.1. Polymerase Chain Reaction (PCR)
15.2.2.2. Next-generation Sequencing (NGS)
15.2.2.3. In Situ Hybridization
15.2.3. Others
15.3. Market Attractiveness, by Detection Technique
15.4. Market Value Forecast, by Biomarker, 2020 - 2034
15.4.1. EGFR
15.4.2. KRAS
15.4.3. HER2
15.4.4. BRAF V600E
15.4.5. Others
15.5. Market Attractiveness, by Biomarker
15.6. Market Value Forecast, by Cancer Type, 2020 - 2034
15.6.1. Breast Cancer
15.6.2. Lung Cancer
15.6.3. Colorectal Cancer
15.6.4. Liver Cancer
15.6.5. Melanoma
15.6.6. Others
15.7. Market Attractiveness, by Cancer Type
15.8. Market Value Forecast, by End-user, 2020 - 2034
15.8.1. Hospitals
15.8.2. Specialty Clinics
15.8.3. Diagnostic Labs
15.8.4. Others
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Detection Technique
15.11.2. By Biomarker
15.11.3. By Cancer Type
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Abbott
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. F. Hoffmann-LA Roche AG
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Genomic Health, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. QIAGEN
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Agilent Technologies, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. AGENDIA N.V.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. bioMérieux SA
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Illumina, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Siemens Healthineers
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Thermo Fisher Scientific Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. BioGenex
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
List of Tables
Table 01: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
Table 02: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
Table 03: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
Table 04: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
Table 05: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Region, 2020 - 2034
Table 06: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country, 2020 - 2034
Table 07: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
Table 08: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
Table 9: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
Table 10: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
Table 11: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034
Table 12: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
Table 13: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
Table 14: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
Table 15: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
Table 16: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034
Table 17: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
Table 18: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
Table 19: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
Table 20: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
Table 21: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034
Table 22: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
Table 23: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
Table 24: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
Table 25: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
Table 26: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034
Table 27: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034
Table 28: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034
Table 29: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034
Table 30: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034
List of Figures
Figure 01: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million), by Region, 2023 - 2034
Figure 02: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Detection Technique, 2023
Figure 03: Global Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2023
Figure 04: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Biomarker, 2023
Figure 05: Global Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2023
Figure 06: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Cancer Type, 2023
Figure 07: Global Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2023
Figure 08: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by End-user, 2023
Figure 09: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2023
Figure 10: Global Companion Diagnostic Tests in Oncology Market Value Share, by Region, 2023
Figure 11: Global Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast, 2020 - 2034
Figure 12: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
Figure 13: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
Figure 14: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
Figure 15: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
Figure 16: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
Figure 17: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
Figure 18: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by End-user, 2023
Figure 19: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2023
Figure 20: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Region, 2023 - 2034
Figure 21: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Region, 2024 - 2034
Figure 22: North America Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
Figure 23: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country, 2024 - 2034
Figure 24: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country, 2023 - 2034
Figure 25: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
Figure 26: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
Figure 27: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
Figure 28: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
Figure 29: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
Figure 30: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
Figure 31: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
Figure 32: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034
Figure 33: Europe Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
Figure 34: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034
Figure 35: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034
Figure 36: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
Figure 37: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
Figure 38: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
Figure 39: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
Figure 40: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
Figure 41: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
Figure 42: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
Figure 43: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034
Figure 44: Asia Pacific Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
Figure 45: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034
Figure 46: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034
Figure 47: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
Figure 48: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
Figure 49: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
Figure 50: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
Figure 51: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
Figure 52: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
Figure 53: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
Figure 54: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2023–2034
Figure 55: Latin America Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
Figure 56: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034
Figure 57: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034
Figure 58: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
Figure 59: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
Figure 60: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
Figure 61: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
Figure 62: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
Figure 63: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
Figure 64: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
Figure 65: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034
Figure 66: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034
Figure 67: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034
Figure 68: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034
Figure 69: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034
Figure 70: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034
Figure 71: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034
Figure 72: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034
Figure 73: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034
Figure 74: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034
Figure 75: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034
Figure 76: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Companion Diagnostic Tests in Oncology Market
*86 figures and 60 tables includes